// App-Quantinova.ai

362 : A PhII study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab in pts with previously-treated advanced NSCLC: Updated clinical & translational analysis

Researchers

Presenter

  • James Spicer

Principal Investigators

  • Enric Carcereny

  • Edurne Arriola

  • Manuel Dmine Gomez

  • Jose Manuel Trigo Perez

  • Jonathan Thompson

  • James Strauss

  • Ana Laura Ortega Granados

  • Enriqueta Felip

  • Emmett Schmidt

  • Michael Chisamore

  • Noelly Madeleine

  • Austin Rayford

  • Katherine Lorens

  • Abdul Siddiqui

  • Hani Gabra

  • Jaya Nautiyal

  • David Micklem

  • James Lorens

  • Matthew Krebs

Medical Centers

  • King’s College London, Guy’s Hospital, London, UK

  • Oslo University Hospital, Oslo, Norway

  • Institut Catal dOncologia Badalona, Badalona, Spain

  • Hospital Del Mar, Barcelona, Spain

  • Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain

  • Hospital Virgen de la Victoria, Malaga, Spain

  • Medcl Coll of Wisconsin, Menomonee Falls, WI

  • Mary Crowley Cancer Research, Dallas, TX, USA

  • Complejo Hospitalario de Jaen, Jaen, Spain

  • Hospital Universitario del Mar, Barcelona, Spain

  • Merck and Co, Inc., Kenilworth, NJ, USA

  • BergenBio AS, Bergen, Norway

  • Christie NHS Foundation, U of Manchester, Manchester, Manchester, UK

Locations

  • United Kingdom

  • Norway

  • Spain

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Lung Cancer

  • Non Small Cell Lung cancer

Biomarkers

  • AXL receptor tyrosine kinase

  • Programmed death-ligand 1

  • Tissue polypeptide-specific antigen

Drug/Treatment

  • Pembrolizumab

  • R428

Outcome

  • N/A

Study Design

  • Single Arm

  • Cohort

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved